vs

Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and S&T BANCORP INC (STBA). Click either name above to swap in a different company.

S&T BANCORP INC is the larger business by last-quarter revenue ($102.1M vs $57.3M, roughly 1.8× RHYTHM PHARMACEUTICALS, INC.). S&T BANCORP INC runs the higher net margin — 34.4% vs -83.0%, a 117.3% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 2.6%).

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

RYTM vs STBA — Head-to-Head

Bigger by revenue
STBA
STBA
1.8× larger
STBA
$102.1M
$57.3M
RYTM
Higher net margin
STBA
STBA
117.3% more per $
STBA
34.4%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
2.6%
STBA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RYTM
RYTM
STBA
STBA
Revenue
$57.3M
$102.1M
Net Profit
$-47.5M
$35.1M
Gross Margin
91.6%
Operating Margin
-82.2%
Net Margin
-83.0%
34.4%
Revenue YoY
36.9%
Net Profit YoY
-9.6%
5.0%
EPS (diluted)
$-0.73
$0.94

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RYTM
RYTM
STBA
STBA
Q1 26
$102.1M
Q4 25
$57.3M
$105.3M
Q3 25
$51.3M
$103.0M
Q2 25
$48.5M
$100.1M
Q1 25
$32.7M
$93.8M
Q4 24
$41.8M
$94.3M
Q3 24
$33.3M
$96.4M
Q2 24
$29.1M
$96.9M
Net Profit
RYTM
RYTM
STBA
STBA
Q1 26
$35.1M
Q4 25
$-47.5M
$34.0M
Q3 25
$-52.9M
$35.0M
Q2 25
$-46.6M
$31.9M
Q1 25
$-49.5M
$33.4M
Q4 24
$-43.3M
$33.1M
Q3 24
$-43.6M
$32.6M
Q2 24
$-32.3M
$34.4M
Gross Margin
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Operating Margin
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
-82.2%
40.3%
Q3 25
-102.6%
42.6%
Q2 25
-93.4%
40.0%
Q1 25
-143.7%
44.5%
Q4 24
-98.6%
43.8%
Q3 24
-132.0%
43.0%
Q2 24
-139.2%
44.2%
Net Margin
RYTM
RYTM
STBA
STBA
Q1 26
34.4%
Q4 25
-83.0%
32.3%
Q3 25
-103.1%
33.9%
Q2 25
-96.1%
31.9%
Q1 25
-151.4%
35.6%
Q4 24
-103.6%
35.1%
Q3 24
-131.2%
33.8%
Q2 24
-110.9%
35.5%
EPS (diluted)
RYTM
RYTM
STBA
STBA
Q1 26
$0.94
Q4 25
$-0.73
$0.88
Q3 25
$-0.82
$0.91
Q2 25
$-0.75
$0.83
Q1 25
$-0.81
$0.87
Q4 24
$-0.71
$0.86
Q3 24
$-0.73
$0.85
Q2 24
$-0.55
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RYTM
RYTM
STBA
STBA
Cash + ST InvestmentsLiquidity on hand
$388.9M
Total DebtLower is stronger
$100.8M
Stockholders' EquityBook value
$139.1M
$1.4B
Total Assets
$480.2M
$9.9B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
$388.9M
$163.4M
Q3 25
$416.1M
$196.2M
Q2 25
$291.0M
$203.1M
Q1 25
$314.5M
$211.8M
Q4 24
$320.6M
$244.8M
Q3 24
$298.4M
$228.1M
Q2 24
$319.1M
$246.3M
Total Debt
RYTM
RYTM
STBA
STBA
Q1 26
$100.8M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
RYTM
RYTM
STBA
STBA
Q1 26
$1.4B
Q4 25
$139.1M
$1.5B
Q3 25
$148.8M
$1.5B
Q2 25
$-11.9M
$1.4B
Q1 25
$18.9M
$1.4B
Q4 24
$21.7M
$1.4B
Q3 24
$11.2M
$1.4B
Q2 24
$39.3M
$1.3B
Total Assets
RYTM
RYTM
STBA
STBA
Q1 26
$9.9B
Q4 25
$480.2M
$9.9B
Q3 25
$506.9M
$9.8B
Q2 25
$372.7M
$9.8B
Q1 25
$386.7M
$9.7B
Q4 24
$392.3M
$9.7B
Q3 24
$363.6M
$9.6B
Q2 24
$381.8M
$9.6B
Debt / Equity
RYTM
RYTM
STBA
STBA
Q1 26
0.07×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RYTM
RYTM
STBA
STBA
Operating Cash FlowLast quarter
$-25.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
$-25.4M
$133.6M
Q3 25
$-26.6M
$40.5M
Q2 25
$-23.3M
$28.3M
Q1 25
$-40.4M
$28.7M
Q4 24
$-18.8M
$173.4M
Q3 24
$-25.2M
$27.6M
Q2 24
$-29.1M
$44.7M
Free Cash Flow
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
$128.8M
Q3 25
$39.9M
Q2 25
$27.1M
Q1 25
$27.0M
Q4 24
$170.4M
Q3 24
$26.9M
Q2 24
$43.9M
FCF Margin
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
122.4%
Q3 25
38.7%
Q2 25
27.1%
Q1 25
28.8%
Q4 24
180.7%
Q3 24
28.0%
Q2 24
45.3%
Capex Intensity
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
4.5%
Q3 25
0.6%
Q2 25
1.2%
Q1 25
1.8%
Q4 24
3.1%
Q3 24
0.7%
Q2 24
0.9%
Cash Conversion
RYTM
RYTM
STBA
STBA
Q1 26
Q4 25
3.93×
Q3 25
1.16×
Q2 25
0.89×
Q1 25
0.86×
Q4 24
5.24×
Q3 24
0.85×
Q2 24
1.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RYTM
RYTM

Segment breakdown not available.

STBA
STBA

Net Interest Income$88.4M87%
Noninterest Income$13.6M13%

Related Comparisons